ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Valirx Stock Is Useless to Sellers

Share On Facebook
share on Linkedin
Print

Valirx stock (LSE:VAL) is not a market in which sellers can currently make money, and therefore, it is useless to them. From January to May 2015, the price moved in an equilibrium zone, and then broke upwards seriously. The price is currently volatile, but things are still in favor of buyers.

4 EMAs are used for this analysis: they are EMAs 10, 20, 50 and 200. The color that stands for each EMA is shown in the top left part of the chart. All the EMAs are currently sloping upwards, allowing a confirmation of a bullish bias. The price may temporarily pull back into the EMA 10 and 20 (or even the EMA 50), proffering buying opportunities.

Further bullish movement is thus expected on Valirx. Though a market prognosis may be beneficial, but that does not mean that one has a guarantee of what would happen tomorrow. When monitoring open positions, one will realize that times of entries and exits are important. When trades are constantly followed, some losses would matter over time.

This forecast is ended by the quote below:

“Mobile Trading has opened up the financial markets to a remarkable degree. No longer are traders forced to stay at their desktops in order to access the markets.” – Joe Rundle

What Super Traders Don’t Want You To Know: Super Traders

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com